Published in Exp Cell Res on April 15, 2002
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst (2002) 3.08
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res (2009) 1.98
Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta (2008) 1.76
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.43
Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat (2003) 1.39
Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med (Maywood) (2004) 1.31
Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. Breast Cancer Res (2007) 1.25
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res (2003) 1.19
Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle (2012) 1.17
Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice. Cancer Epidemiol Biomarkers Prev (2002) 1.05
The EGF/ErbB receptor family and apoptosis. Growth Factors (2002) 1.04
Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci (2010) 1.03
Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res (2008) 1.02
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.01
Prevention of mammary tumorigenesis by intermittent caloric restriction: does caloric intake during refeeding modulate the response? Exp Biol Med (Maywood) (2007) 1.00
Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment. Cell Cycle (2012) 0.99
A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro Oncol (2002) 0.98
EGFR isoforms and gene regulation in human endometrial cancer cells. Mol Cancer (2010) 0.97
Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann N Y Acad Sci (2003) 0.97
Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer. IDrugs (2009) 0.97
Diet-induced obesity and mammary tumor development in MMTV-neu female mice. Nutr Cancer (2004) 0.94
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Res (2005) 0.94
Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases. Prostate (2004) 0.94
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. J Ovarian Res (2010) 0.93
EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 0.90
Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-Neu female mice. Nutr Cancer (2002) 0.89
The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. J Soc Gynecol Investig (2006) 0.87
Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo. Arthritis Res Ther (2013) 0.87
Requirement for ErbB2/ErbB signaling in developing cartilage and bone. Dev Growth Differ (2007) 0.86
Shedding of soluble epidermal growth factor receptor (sEGFR) is mediated by a metalloprotease/fibronectin/integrin axis and inhibited by cetuximab. Biochemistry (2013) 0.86
Studies on epidermal growth factor receptor signaling in vertebrate limb patterning. Dev Dyn (2005) 0.84
Generation and characterization of polyclonal antibodies specific for human p110 sEGFR. Hybrid Hybridomics (2002) 0.83
The epidermal growth factor receptor conundrum. Cancer (2010) 0.83
Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer. Cancer Treat Res (2009) 0.80
Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin. Biochemistry (2011) 0.79
Therapeutic potential of epidermal growth factor receptor-related protein. Mol Cancer Ther (2006) 0.78
Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis. Oncogene (2003) 0.77
Searching for a system: the quest for ovarian cancer biomarkers. Cancer Biomark (2011) 0.76
Soluble epidermal growth factor receptor acridinium-linked immunosorbent assay. Methods Mol Biol (2006) 0.76
Receptor tails and transcriptional regulation. Trends Cell Biol (2002) 0.75
Membrane localization of v-ErbB is required but not sufficient for ligand-independent transformation. Exp Cell Res (2004) 0.75